8月12日，微创医疗科学有限公司（00853.HK）发布截至2026年6月30日止六个月之中期业绩预告。一面是经营层面的全面改善，另一面却是净亏损的持续未止。 根据公告，本集团持续经营业务收入实现同比约12%至14%的增长，尤其出海业务继续贡献约140%的强劲增长。持续经营业务毛利率同比提升约3至4个百分点，持续推进精细化运营及费用管控。期间内，持续经营业务录得经营性净利润不低于2400万美元，...
Source Link8月12日，微创医疗科学有限公司（00853.HK）发布截至2026年6月30日止六个月之中期业绩预告。一面是经营层面的全面改善，另一面却是净亏损的持续未止。 根据公告，本集团持续经营业务收入实现同比约12%至14%的增长，尤其出海业务继续贡献约140%的强劲增长。持续经营业务毛利率同比提升约3至4个百分点，持续推进精细化运营及费用管控。期间内，持续经营业务录得经营性净利润不低于2400万美元，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.